Identification of three novel peptides that inhibit CD40-CD154 interaction

Modern Rheumatology

Volumn 15, Issue 6, 2005, Pages 423-426

  Kitagawa, Minetake ^a   Goto, Daisuke ^a   Mamura, Mizuko ^a   Matsumoto, Isao ^a   Ito, Satoshi ^a   Tsutsumi, Akito ^a   Sumida, Takayuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Autoimmune disease; CD154; CD40; Peptide; Phage display

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; IMMUNOGLOBULIN; PEPTIDE DERIVATIVE;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; BINDING ASSAY; CONSENSUS SEQUENCE; CONTROLLED STUDY; DRUG INHIBITION; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; PEPTIDE ANALYSIS; PRIORITY JOURNAL;

EID: 31144460536     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-005-0442-6     Document Type: Article

References (11)

1. TM. Foy A. Aruffo J. Bajorath JE. Buhlmann RJ. Noelle Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 1996;14: 591-617. 10.1146/ annurev.immunol.14.1.591 8717526 1:CAS:528:DyaK28XitlCgtbk%3D
2. D, Hollenbaugh HD, Ochs RJ, Noelle JA, Ledbetter A, Aruffo The role of CD40 and its ligand in the regulation of the immune response. Immunol Rev 1994;138: 23-37. 7520883 1:CAS:528:DyaK2cXkvVSnsb8%3D
3. FH, Durie RA, Fava TM, Foy A, Aruffo JA, Ledbetter RJ, Noelle Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993;261(5126): 1328-30. 7689748 1:CAS:528:DyaK3sXlsFyit7s%3D A1993LV65600030
4. C, Mohan Y, Shi JD, Laman SK, Datta Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995;154(3): 1470-80. 7529804 1:CAS:528:DyaK2MXjt1Krs7s%3D
5. LM, Howard AJ, Miga CL, Vanderlugt MC, Dal Canto JD, Laman RJ, Noelle Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J Clin Invest 1999;103(2): 281-90. 9916140 1:CAS:528:DyaK1MXltFCjsA%3D%3D
6. LM, Howard MC, Dal Canto SD, Miller Transient anti-CD154-mediated immunotherapy of ongoing relapsing experimental autoimmune encephalomyelitis induces long-term inhibition of disease relapses. J Neuroimmunol 2002;129(1-2): 58-65. 12161021 1:CAS:528:DC%2BD38XlvVers78%3D
7. WC, Fanslow DM, Anderson KH, Grabstein EA, Clark D, Cosman RJ, Armitage Soluble forms of CD40 inhibit biologic responses of human B cells. J Immunol 1992;149(2):655-60. 1378075 1:CAS:528:DyaK38XltV2ltb0%3D
8. D, Hollenbaugh J, Douthwright V, McDonald A, Aruffo Cleavable CD40Ig fusion proteins and the binding to sgp39. J Immunol Methods 1995;188(1):1-7. 10.1016/0022-1759(95)00194-8 8551028 1:CAS:528:DyaK2MXpvV2isrk%3D
9. D, Hollenbaugh LS, Grosmaire CD, Kullas NJ, Chalupny S, Braesch-Andersen RJ, Noelle The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: Expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J 1992;11(12):4313-21. 1385114 1:CAS:528:DyaK3sXkvFeiurk%3D A1992JY10100007
10. SH, Im D, Barchan PK, Maiti S, Fuchs MC, Souroujon Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4. J Immunol 2001;166(11):6893-8. 11359850 1:CAS:528:DC%2BD3MXjvFaqs74%3D
11. K, Matsui JJ, Boniface PA, Reay H, Schild B, Fazekas de St Groth MM, Davis Low affinity interaction of peptide-MHC complexes with T cell receptors. Science 1991;254:1788-91. 1763329 1:CAS:528:DyaK38Xls12hug%3D%3D A1991GW31600042